↓ Skip to main content

Cochrane Database of Systematic Reviews

Immunotherapy for diabetic amyotrophy

Overview of attention for article published in Cochrane database of systematic reviews, July 2017
Altmetric Badge

About this Attention Score

  • Above-average Attention Score compared to outputs of the same age (53rd percentile)

Mentioned by

5 tweeters


28 Dimensions

Readers on

173 Mendeley
Immunotherapy for diabetic amyotrophy
Published in
Cochrane database of systematic reviews, July 2017
DOI 10.1002/14651858.cd006521.pub4
Pubmed ID

Yee Cheun Chan, Yew Long Lo, Edwin SY Chan


People with diabetes mellitus (DM) sometimes present with acute or subacute, progressive, asymmetrical pain and weakness of the proximal lower limb muscles. The various names for the condition include diabetic amyotrophy, diabetic lumbosacral radiculoplexus neuropathies, diabetic femoral neuropathy or Bruns-Garland syndrome. Some studies suggest that diabetic amyotrophy may be an immune-mediated inflammatory microvasculitis causing ischaemic damage of the nerves. Immunotherapies would therefore be expected to be beneficial. This is the second update of a review first published in 2009. To review the evidence from randomised trials for the efficacy of any form of immunotherapy in the treatment of diabetic amyotrophy. On 5 September 2016 we searched the Cochrane Neuromuscular Specialised Register, CENTRAL, MEDLINE and Embase. We also contacted authors of relevant publications and other experts to obtain additional references, unpublished trials, and ongoing trials. We intended to include all randomised and quasi-randomised trials of any immunotherapy in participants with the condition fulfilling all the following: diabetes mellitus as defined by internationally recognised criteria; acute or subacute onset of pain and lower motor neuron weakness involving predominantly the proximal muscles of the lower limbs; weakness that is not confined to one nerve or nerve root distribution; and exclusion of other causes of lumbosacral radiculopathies and plexopathy. Two authors independently examined all references retrieved by the search to select those meeting the inclusion criteria. We found only one completed placebo-controlled trial (N = 75) using intravenous methylprednisolone in diabetic amyotrophy (Dyck 2006). The results have not been fully published and were not available for analysis. The risk of bias was unclear because there was too little information to make a judgement, but we considered the trial at high risk of selective reporting. The published abstract did not report adverse events. We found no additional trials when the searches were updated in September 2016. There is presently no evidence from randomised trials to support a positive or negative effect of any immunotherapy in the treatment in diabetic amyotrophy.

Twitter Demographics

Twitter Demographics

The data shown below were collected from the profiles of 5 tweeters who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 173 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Japan 1 <1%
Unknown 172 99%

Demographic breakdown

Readers by professional status Count As %
Student > Master 22 13%
Student > Bachelor 17 10%
Unspecified 15 9%
Researcher 14 8%
Other 13 8%
Other 47 27%
Unknown 45 26%
Readers by discipline Count As %
Medicine and Dentistry 59 34%
Unspecified 15 9%
Nursing and Health Professions 12 7%
Neuroscience 9 5%
Agricultural and Biological Sciences 6 3%
Other 25 14%
Unknown 47 27%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 02 August 2017.
All research outputs
of 22,994,508 outputs
Outputs from Cochrane database of systematic reviews
of 12,348 outputs
Outputs of similar age
of 317,089 outputs
Outputs of similar age from Cochrane database of systematic reviews
of 272 outputs
Altmetric has tracked 22,994,508 research outputs across all sources so far. This one is in the 44th percentile – i.e., 44% of other outputs scored the same or lower than it.
So far Altmetric has tracked 12,348 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 30.6. This one is in the 20th percentile – i.e., 20% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 317,089 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 53% of its contemporaries.
We're also able to compare this research output to 272 others from the same source and published within six weeks on either side of this one. This one is in the 22nd percentile – i.e., 22% of its contemporaries scored the same or lower than it.